Navigation Links
Cardiff scientists study acute infection in end-stage kidney disease patients
Date:11/13/2008

A new research study underway at Cardiff University could see a decrease in the rates of treatment failure among patients with end-stage kidney disease.

Experts in the Infection, Immunity and Inflammation Interdisciplinary Research Group at the School of Medicine have secured more than 230,000 ($375,000) from the 'Renal Discoveries - The Baxter Extramural Grant' program, to investigate the potential to safeguard susceptible patients against serious problems caused by bacterial infections.

Each year Baxter Healthcare Corporation awards the Baxter Extramural Grant for innovation, exploration and application of research to advance the knowledge of renal conditions and its treatment. With only four grants awarded world-wide each year, Cardiff University is the sole recipient of the funding for the Europe/Middle East/Africa and Russia region.

Bacterial infection among patients with end-stage kidney disease is one of the major reasons for treatment failure and mortality, particularly among patients receiving peritoneal dialysis, the form of dialysis that cleans the blood inside the body through the peritoneum.

Now, thanks to the three year funding, the multidisciplinary team sponsored by Professor of Medicine John Williams, at Cardiff University will begin studying the consequence of infection by bacteria in order to understand, and in the future better regulate, a patient's immune response to infections. The team brings together clinicians and researchers at the Peritoneal Dialysis Unit, the Institute of Nephrology, and the Department of Medical Biochemistry and Immunology.

Dr Matthias Eberl, principal investigator at the Department of Medical Biochemistry and Immunology, said: "Although peritoneal dialysis has a number of advantages such as independence from hospital and improved quality of life, infections still pose major risks to the patient. As treatment failure in these patients correlates directly with the severity of the inflammatory response and antibiotic resistance is becoming a significant problem, we need to understand why some patients are more prone to treatment failure than others."

The Baxter grant also includes a three-year visiting fellowship for a peritoneal dialysis specialist from Chang Gung Memorial Hospital in Taiwan. Dr Chan-Yu Lin will conduct his PhD studies at Cardiff University on peritoneal dialysis-related infections and receive training in early treatment of inflammation, microbiological diagnosis, and analysis of patient samples in the laboratory.

Dr Eberl said: "We are studying the immune response in peritoneal dialysis patients during episodes of bacterial peritonitis to improve current ways of infection prevention and therapy. However, the scope of our work is much wider in the context of infectious and inflammatory disease in other organs and in sepsis."

Earlier this year Dr Eberl's team together with Professor Nicholas Topley at the Department of Medical Biochemistry and Immunology were awarded a Welsh Assembly Government /Medical Research Council Health Research Partnership Award from the Wales Office of Research and Development for their work on peritoneal dialysis-related infection.


'/>"/>

Contact: Dr Matthias Eberl
eberlm@cardiff.ac.uk
Cardiff University
Source:Eurekalert

Related medicine news :

1. Scientists Unravel Mystery of Tamoxifen Resistance
2. Freezing Ovaries Preserves Fertility, Scientists Report
3. TSODs Frank Whyte Provides Negotiation Skills Training to NIH Scientists
4. Scientists Debate Dietary Supplements and Cancer Risk at AICR Conference
5. Penn scientists show how body determines optimal amount of germ-fighting B cells
6. Penn scientists map molecular regulation of fat-cell genetics
7. Scientists Make Clones of Mice Dead 16 Years
8. Anti-VEGF drugs for retinal diseases could have serious side effects, scientists caution
9. Anti-VEGF Drugs for Retinal Diseases Could Have Serious Side Effects, Scientists Caution
10. Scientists Develop New Strategy to Fight Obesity
11. Scientists Spot 4 New Alzheimers Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
Breaking Medicine Technology: